Display options
Cite
Molaahmadi MR, Varshosaz J, Taymouri S, et al. Lipid Nanocapsules for Imatinib Delivery: Design, Optimization and Evaluation of Anticancer Activity Against Melanoma Cell Line. Iran J Pharm Res. 2019;18(4):1676-1693doi: 10.22037/ijpr.2019.1100870.
Molaahmadi, M. R., Varshosaz, J., Taymouri, S., & Akbari, V. (2019). Lipid Nanocapsules for Imatinib Delivery: Design, Optimization and Evaluation of Anticancer Activity Against Melanoma Cell Line. Iranian journal of pharmaceutical research : IJPR, 18(4), 1676-1693. https://doi.org/10.22037/ijpr.2019.1100870
Molaahmadi, Mohammad Reza, et al. "Lipid Nanocapsules for Imatinib Delivery: Design, Optimization and Evaluation of Anticancer Activity Against Melanoma Cell Line." Iranian journal of pharmaceutical research : IJPR vol. 18,4 (2019): 1676-1693. doi: https://doi.org/10.22037/ijpr.2019.1100870
Molaahmadi MR, Varshosaz J, Taymouri S, Akbari V. Lipid Nanocapsules for Imatinib Delivery: Design, Optimization and Evaluation of Anticancer Activity Against Melanoma Cell Line. Iran J Pharm Res. 2019;18(4):1676-1693. doi: 10.22037/ijpr.2019.1100870. PMID: 32184838; PMCID: PMC7059069.
Copy Download .nbib Format: NLM
Share it on

Iran J Pharm Res. 2019;18(4):1676-1693. doi: 10.22037/ijpr.2019.1100870.

Lipid Nanocapsules for Imatinib Delivery: Design, Optimization and Evaluation of Anticancer Activity Against Melanoma Cell Line.

Iranian journal of pharmaceutical research : IJPR

Mohammad Reza Molaahmadi, Jaleh Varshosaz, Somayeh Taymouri, Vajihe Akbari

Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
  2. Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.
  3. Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 32184838 PMCID: PMC7059069 DOI: 10.22037/ijpr.2019.1100870

Abstract

Lipid nanocapsules (LNCs) represent a stable, biocompatible and worthwhile drug delivery system, demonstrating significant potential as gene/drug delivery platforms for cancer therapy. Imatinib, a potent tyrosine kinase inhibitor, has revolutionized the therapy of malignancies resulting from abnormal tyrosine kinase activity. However, its Clinical effectiveness in cancer treatment is hampered by its off-target side effects. In this study, we have investigated the potential benefits of LNCs as a novel drug delivery vehicle for imatinib with a view to improve drug efficacy. LNC formulations were prepared by phase-inversion temperature method and the effects of various formulation variables were assessed using full factorial design. The cytotoxicity and cellular uptake of optimized formulation were investigated against B16F10 melanoma cell line. Analysis of result by Design-Expert® software indicated that Solutol HS15 percent was the most effective parameter on the encapsulation efficiency, particle size, zeta potential, and release efficiency of LNCs. The optimized formulation revealed a particle size of 38.96 ± 0.84 nm, encapsulation efficiency of 99.17 ± 0.086%, zeta potential of -21.5 ± 0.61 mV, release efficiency of 60.03 ± 4.29, and polydispersity index of 0.24 ± 0.02. The imatinib loaded LNCs showed no hemolysis activity. Fluorescent microscopy test showed that the cellular uptake of LNCs was time dependent and density of fluorescent signals increased with time in cells. The

Keywords: B16F10 melanoma cells; Cancer chemotherapy; Imatinib; Lipid nanocapsules; Phase-inversion temperature method

References

  1. Pharm Res. 2002 Jun;19(6):875-80 - PubMed
  2. J Colloid Interface Sci. 2017 Jun 15;496:201-210 - PubMed
  3. Int J Pharm. 2010 Jan 4;383(1-2):178-85 - PubMed
  4. Urol Oncol. 2008 Jan-Feb;26(1):57-64 - PubMed
  5. Blood. 2004 Sep 1;104(5):1442-9 - PubMed
  6. Res Pharm Sci. 2015 Jan-Feb;10(1):17-33 - PubMed
  7. Colloids Surf B Biointerfaces. 2009 Mar 1;69(2):157-63 - PubMed
  8. J Drug Deliv. 2011;2011:571272 - PubMed
  9. Case Rep Oncol. 2017 Jun 22;10(2):558-563 - PubMed
  10. Biotechnol Bioeng. 2010 Dec 1;107(5):884-93 - PubMed
  11. IET Nanobiotechnol. 2015 Oct;9(5):306-13 - PubMed
  12. Acta Biomater. 2010 Jun;6(6):2045-52 - PubMed
  13. Int J Biol Macromol. 2015 Feb;73:222-35 - PubMed
  14. Biomaterials. 2010 May;31(13):3657-66 - PubMed
  15. Curr Drug Targets. 2014;15(9):829-42 - PubMed
  16. Int J Nanomedicine. 2013;8:4291-302 - PubMed
  17. Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:55-63 - PubMed
  18. Biomaterials. 2015 Aug;61:266-78 - PubMed
  19. Int J Pharm. 2012 Jul 1;430(1-2):350-8 - PubMed
  20. J Control Release. 2006 May 15;112(2):208-13 - PubMed
  21. Eur J Pharm Biopharm. 2012 Jun;81(2):448-52 - PubMed
  22. Nanoscale Res Lett. 2009 Sep 16;4(12):1502-11 - PubMed
  23. Int J Nanomedicine. 2012;7:4391-408 - PubMed
  24. Pharm Res. 2010 Mar;27(3):421-30 - PubMed
  25. Pharm Res. 2006 Jun;23(6):1243-50 - PubMed
  26. J Microencapsul. 2011;28(8):729-42 - PubMed
  27. Int J Pharm. 2009 Sep 11;379(2):270-7 - PubMed
  28. Eur J Pharm Sci. 2003 Jan;18(1):55-61 - PubMed
  29. Drug Dev Ind Pharm. 2018 Feb;44(2):276-288 - PubMed
  30. Int J Nanomedicine. 2014 May 07;9:2167-78 - PubMed
  31. Int J Pharm. 2014 Aug 25;471(1-2):485-97 - PubMed
  32. J Nanosci Nanotechnol. 2015 Apr;15(4):2643-9 - PubMed
  33. Eur J Pharm Sci. 2013 Oct 9;50(2):172-80 - PubMed
  34. Int J Nanomedicine. 2015 Apr 24;10:3163-70 - PubMed
  35. Nanotechnology. 2009 Feb 4;20(5):055106 - PubMed
  36. Biomaterials. 2006 Jul;27(21):4025-33 - PubMed
  37. Int J Pharm. 2009 Sep 11;379(2):201-9 - PubMed
  38. J Control Release. 2009 Oct 1;139(1):56-62 - PubMed
  39. J Liposome Res. 2017 Mar;27(1):1-10 - PubMed
  40. J Control Release. 2008 Sep 10;130(2):146-53 - PubMed
  41. J Control Release. 2002 Nov 7;84(1-2):59-68 - PubMed
  42. Pharm Dev Technol. 2015 Nov;20(7):791-800 - PubMed

Publication Types